Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
Alberto
A
Muñoz
José Ramón
JR
Barceló
Guillermo
G
López-Vivanco
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001707:Biopsy, Needle; D002277:Carcinoma / Q000188:drug therapy / Q000556:secondary*; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D009382:Neoplasms, Unknown Primary / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D018570:Risk Assessment; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage*; D016896:Treatment Outcome; D000093542:Gemcitabine
D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000093542:Gemcitabine